| Daniel Byron Miller, MD | |
|
401 W Poplar St, Psmmc Er, Walla Walla, WA 99362-2846 | |
| (509) 522-5802 | |
| (509) 522-5541 |
| Full Name | Daniel Byron Miller |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 401 W Poplar St, Walla Walla, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588678999 | NPI | - | NPPES |
| 1588678999 | Medicaid | WA | |
| 130169 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD00032169 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Byron Miller, MD Po Box 34439, Seattle, WA 98124-1439 Ph: () - | Daniel Byron Miller, MD 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362-2846 Ph: (509) 522-5802 |
News Archive
Daiichi Sankyo Company, Limited (TSE: 4568) announced today that it has successfully completed patient enrollment for its Phase III ENGAGE AF-TIMI 48 clinical study of edoxaban, a direct, specific, oral Factor Xa inhibitor that is being investigated in two different dosing regimens given once daily, to prevent the occurrence of strokes and systemic embolic events (SEE) in patients with atrial fibrillation (AF).
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.
An experimental vaccine against the Ebola virus has proved effective and well-tolerated in the first human trial of a candidate Ebola drug.
A group of drugs commonly prescribed for insomnia, anxiety and breathing issues "significantly increase the risk" that older people with chronic obstructive pulmonary disease, or COPD, need to visit a doctor or Emergency Department for respiratory reasons, new research has found.
› Verified 8 days ago
Dr. Philip A Green, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Shirley Robin Vonhaven, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 W Poplar, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5950 | |
Jared L Wutzke, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Dr. Morgan C Galante, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 S 2nd Ave, Walla Walla, WA 99362 Phone: 509-897-3700 | |
Joilo Barbosa, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 E Main St # 268, Walla Walla, WA 99362 Phone: 509-529-2966 | |
Aaron B Jones, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Emergency Department, Walla Walla, WA 99362 Phone: 509-525-3320 | |
Eric Trent Brown, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 |